US Drugmakers Are Dependent on Chinese Supply Chains

The Diplomat | Mitch Shin

China controls the upstream production chemistry for critical generic pharmaceuticals used in the United States, exposing American healthcare to critical supply vulnerabilities ahead of Chinese leader Xi Jinping’s September 24 state visit to Washington. According to a September 2 report by Scalare Advisors, China supplied over 70 percent of U.S.

antibiotic active ingredient imports by volume in 2024. This concentration creates unprecedented leverage. Common outpatient antibiotics including amoxicillin, azithromycin, and ciprofloxacin rely heavily on Chinese-manufactured precursor materials with no alternative domestic scale capacity. A single Chinese conglomerate, CSPC Pharmaceutical Group, controls the complete fermentation-to-tablet chain for both amoxicillin and azithromycin destined for American patients. Domestic resilience eroded after Bristol-Myers Squibb closed the last U.S. penicillin fermentation plant in 2004, ending domestic production of key precursor 6-aminopenicillanic acid. Disruption of these supply chains would leave American healthcare providers without scalable outpatient remedies during severe bilateral or regional geopolitical crises.

Comment

Monopolisation of 6-aminopenicillanic acid precursor chemical synthesis creates a single point of failure in Western pharmaceutical infrastructure. By capturing the complete synthesis pipeline for amoxicillin and azithromycin, CSPC Pharmaceutical Group holds a structural bottleneck over essential antimicrobial production. This structural dominance converts primary chemical manufacturing into strategic leverage without requiring overt embargoes.

A comparable structural vulnerability emerged during the 1973 OPEC oil embargo, when concentration of crude extraction and refining capacity enabled Middle Eastern producers to disrupt Western industrial supply chains. The complete shuttering of the Bristol-Myers Squibb penicillin fermentation plant in 2004 similarly removed the domestic surge capacity required to buffer against targeted supply cutoffs.

Strategic Question for Discussion

If market forces continue to concentrate the synthesis of 6-aminopenicillanic acid within single entities like CSPC Pharmaceutical Group, can state-directed industrial subsidies successfully rebuild domestic surge capacity, or does the loss of foundational chemical manufacturing permanently cap national crisis resilience?

The trajectory indicates that financial subsidies alone cannot swiftly offset decades of offshored chemical infrastructure, as rebuilding specialized synthesis facilities like the former Bristol-Myers Squibb penicillin plant requires years of regulatory approvals and environmental permitting. Consequently, near-term industrial policy will likely rely on strategic stockpiling rather than rapid domestic manufacturing restoration when facing concentrated bottlenecks like those controlled by CSPC Pharmaceutical Group.

Share your assessment in the comments below.

To read in details click here